# US 2024/0002945 A1 · Graphene-based biosensor and detection method using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002945 A1
- Document ID: US20240002945A1
- Status: Published application
- Kind: A1
- Application number: 18/038,454
- Filed: 2021-11-18
- Published: 2024-01-04
- Earliest claimed: 2020-11-24
- Assignees: Korea Institute of Science and Technology
- Applicants: Korea Institute of Science and Technology
- Inventors: Kwan Hyi LEE; Youngdo JEONG; Ho Jun KIM; Sungwook PARK; Seongchan KIM
- Web page: https://patentgrep.com/patent/US20240002945A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6834: Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 1/6851: Quantitative amplification
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure relates to a biosensor with surface-modified with reduced graphene oxide and a detection method using the same. The biosensor according to an aspect can effectively detect a target material in a urine sample, and thus, the use of the biosensor has an advantage in that prostate cancer can be diagnosed in a non-invasive, fast, and accurate manner.

## Claims

### Claim 1

A biosensor comprising a reaction unit in which an interaction occurs physically or chemically with a target material in a sample, wherein
the reaction unit comprises reduced graphene oxide (rGO).

### Claim 2 (depends on 1)

The biosensor of claim 1, wherein the reaction unit comprises: a substrate; an electrode formed on the substrate; and an rGO layer formed on the electrode.

### Claim 3 (depends on 1)

The biosensor of claim 1, wherein the reaction unit comprises a biological probe that specifically binds to the target material.

### Claim 4 (depends on 3)

The biosensor of claim 3, wherein the biological probe comprises one or more selected from the group consisting of DNA, RNA, PNA, a nucleotide, a nucleoside, a protein, a polypeptide, a peptide, an amino acid, a carbohydrate, an enzyme, an antibody, an antigen, a receptor, a virus, a substrate, a ligand, and a membrane.

### Claim 5 (depends on 3)

The biosensor of claim 3, wherein the biological probe is for detecting one or more miRNAs selected from the group consisting of miRNA21, miRNA1246, and let7b.

### Claim 6 (depends on 3)

The biosensor of claim 3, wherein the reaction unit comprises a linker to immobilize the biological probe on a surface of the electrode.

### Claim 7 (depends on 6)

The biosensor of claim 6, wherein the linker comprises one or more selected from the group consisting of compounds comprising biotin, avidin, streptavidin, carbohydrate, poly L-lysine, a hydroxyl group, a thiol group, an amine group, an alcohol group, a carboxyl group, an amino group, a sulfur group, an aldehyde group, a carbonyl group, a succinimide group, a maleimide group, an epoxy group, and an isothiocyanate group.

### Claim 8 (depends on 1)

The biosensor of claim 1, wherein the target material comprises one or more selected from the group consisting of an antigen, a haptene, a carbohydrate, a protein, a drug, a microorganism, an antibody, and a nucleic acid capable of participating in a sequence-specific hybridization reaction with a complementary sequence.

### Claim 9 (depends on 1)

The biosensor of claim 1, wherein the biosensor is capable of detecting the target material in a urine sample.

### Claim 10 (depends on 1)

The biosensor of claim 1, wherein the target material is a prostate cancer marker.

### Claim 11 (depends on 1)

The biosensor of claim 1, wherein the biosensor further comprises a signal converter that recognizes and converts the interaction into an electrical signal, and the reaction unit is separable from the signal converter.

### Claim 12 (depends on 11)

The biosensor of claim 11, wherein the signal converter comprises a field-effect transistor (FET).

### Claim 13 (depends on 12)

The biosensor of claim 12, wherein the FET comprises: a substrate; an insulating layer; a source electrode and a drain electrode that are spaced apart from each other; a gate electrode; and a channel layer arranged between the source electrode and the drain electrode.

### Claim 14 (depends on 1)

A method of detecting a target material, the method comprising: contacting a sample to the biosensor of claim 1; and observing a change in electrical conductivity of the biosensor.

### Claim 15 (depends on 14)

The method of claim 14, wherein the reaction unit comprises a biological probe that specifically binds to the target material; and wherein the biological probe is for detecting one or more miRNAs selected from the group consisting of miRNA21, miRNA1246, and let7b.

### Claim 16 (depends on 14)

The method of claim 14, wherein the biosensor is capable of detecting the target material in a urine sample.

### Claim 17 (depends on 14)

The method of claim 14, wherein the target material is a prostate cancer marker.

### Claim 18 (depends on 1)

A method of providing information on the diagnosis of prostate cancer, the method comprising: measuring an expression level of a prostate cancer marker by using the biosensor of claim 1, from a biological sample isolated from a subject.

### Claim 19 (depends on 18)

The method of claim 18, wherein the prostate cancer marker comprise one or more selected from the group consisting of miRNA21, miRNA1246, and let7b.
